Why the study?
The study was designed to describe QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine and its combinations for COVID-19 treatment.
What factors are associated with critical QTc prolongation in hospitalized COVID-19 patients receiving hydroxychloroquine?
What factors are associated with critical QTc prolongation in hospitalized COVID-19 patients receiving hydroxychloroquine?
Diabetes mellitus and concomitant oseltamivir use significantly increase the risk of critical QTc prolongation in COVID-19 patients treated with hydroxychloroquine.
May warrant enhanced QTc monitoring in patients with diabetes or oseltamivir use; hypothesis-generating for COVID-19 risk stratification.
The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation.
No takes yet. Share an insight, caveat, or question.
Çelik et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: